the AIDS@30 Symposium Program

Transcription

Organized by the Harvard School of Public Health | December 1–2, 2011
Engaging to End the Epidemic
Table of Contents
Welcome Message from Julio Frenk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Welcome Message from Richard Marlink . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Global Advisory Council Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Steering Committee Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Sub-Committee Co-Chairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Welcome Message from Staffan Hildebrand—
From Stigma to Hope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Symposium Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Opening and Closing Remarks: Speaker Biographies. . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Session 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Session 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Session 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Session 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Session 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Session 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Session 7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
AIDS@30 Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Symposium Attendee List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Table of Contents | AIDS@30 Engaging to End the Epidemic
1
Welcome Message from
Dean Julio Frenk
AIDS remains the largest public health crisis in the history of humankind, in terms of cases, number of
deaths, people affected, and global pervasiveness. But the tragedy of the epidemic is also remarkable
because it has generated an unprecedented global response. There is much to learn from it.
A vigorous scientific response has generated critical knowledge about the disease and its prevention
and treatment. The benefits of this research have spilled over to improve care for people with other
diseases. AIDS has also elicited a cultural response, inspiring artistic expression and, because of the early
focalization of the epidemic, a cultural transformation. AIDS forced societies to confront how we deal
with stigma, discrimination, and questions of sexuality.
HIV/AIDS has generated a level of political mobilization and financial commitments in civil society that
is also unprecedented. Once we had an effective way of treating AIDS, negotiations and agreements
were able to increase access to antivirals, for example. A new focus of governance emerged to
mobilize international collective action and financing organizations like UNAIDS and the Global Fund
were created.
From the first moment of the epidemic, Harvard University has taken a leading role and made seminal
contributions to all aspects of the response. University researchers contributed major knowledge about
the disease and control strategies. Harvard School of Public Health was at the forefront debating issues
of human rights around AIDS, launching numerous initiatives, international collaborations, participating
in PEPFAR, proposing ideas, and advising on new forms of policy responses.
Unique among the other anniversary look-backs, we are hosting this international symposium to
encompass all these dimensions as we draw lessons from the exemplary response to the HIV/AIDS
epidemic. Obviously much remains to be done. Let us together see if out of the lessons, we can devise
the next stage of response to end this epidemic.
Julio Frenk, MD, MPH, PhD
Chair, AIDS@30 Global Advisory Council
Dean of the Faculty, Harvard School of Public Health
T & G Angelopoulos Professor of Public Health and international Development,
Harvard School of Public Health and Harvard Kennedy School of Government
2
AIDS@30 Engaging to End the Epidemic | Welcome Message from Dean Frenk
Welcome Message from
Richard Marlink
In 1980/81, during my internship at St. Vincent’s Hospital in Greenwich Village, I first encountered
patients with unusual clinical presentations due to a virus yet to be described. Like many of us, I have
combated that virus ever since. Also like many of us who have lost loved ones to AIDS, many of my
patients, colleagues, and friends are now gone because of this virus.
We’re tired of this virus, this epidemic, and now hopefully are able to plan its demise.
We’ve invited you and other key thought leaders in medicine, science, arts, advocacy, public health,
and government to join us in a rigorous discussion of what we have learned about HIV/AIDS over the
past 30 years and together plan for the end of the epidemic. I, for one, do not want to be discussing
AIDS at 40 years or AIDS at 50 years. The conversation starts now, for planning the end of AIDS.
We have used three programmatic lenses to focus broad session topics and our discussions over the
next two days:
s 3CIENCE -EDICINE AND 0UBLIC (EALTH
s !RTS !DVOCACY AND !CTIVISM
s 'OVERNANCE ,EADERSHIP AND &INANCING
Through these lenses, we seek multi-disciplinary, interactive sessions to truly engage all of us in planning
what it will take to end the epidemic. With the beginnings of the scale-up of HIV prevention, care and
treatment efforts worldwide, and with recent scientific advances, we’re at a global tipping point. We
have the medical ability to prevent virtually all new HIV infections in infants and young children. Recent
studies have also shown antiretroviral therapy can greatly reduce the chance of transmitting HIV in
adults. Expanded AIDS funding, innovative financing mechanisms and new efficiencies have increased
access and saved millions of lives. The end is within our grasp, but the end game will not be easy.
We’d like to emerge from this symposium with a declaration that we can take forward; declaring that
now’s the time to be bold, to expand our efforts, and to plan for the end of AIDS. We’d like to call on our
institutions, governments, and global agencies to begin the planning for the virtual end of not only the
pediatric epidemic, but the virtual end to AIDS—period.
Let’s plan to put an end to these decade anniversaries. Let’s take what we’ve learned over 30 years
of fighting to plan what we can do to actually stop another 30 years of preventable infections and
lives lost.
Thank you for joining us in this conversation.
Ric
Richard Marlink, MD
Program Chair, AIDS@30
Bruce A. Beal, Robert L. Beal, and Alexander S. Beal Professor of the Practice of Public Health,
Harvard School of Public Health
Executive Director of the Harvard School of Public Health AIDS Initiative
Senior Advisor, Elizabeth Glaser Pediatric AIDS Foundation
Welcome Message from Richard Marlink | AIDS@30 Engaging to End the Epidemic
3
Global Advisory Council
Stefano Bertozzi
Bill & Melinda Gates Foundation
Gottfried Hirnschall
World Health Organization
Kevin De Cock
Centers for Disease Control
and Prevention
Elly Katabira
International AIDS Society
Anthony Fauci
National Institutes of Health
Harvey Fineberg
Institute of Medicine
Julio Frenk
Helene Gayle
CARE USA
Eric Goosby
U.S. Department of State
4
Michel Kazatchkine
The Global Fund to Fight AIDS,
Tuberculosis and Malaria
Charles Lyons
Elizabeth Glaser Pediatric
AIDS Foundation
Richard Marlink
Michael Merson
Duke Global Health Institute
AIDS@30 Engaging to End the Epidemic | Global Advisory Council
Sigrun Møgedal
The Norwegian Knowledge
Centre for the Health Services
Peter Piot
London School of Hygiene &
Tropical Medicine
David Scheer
Scheer & Company, Inc.
Michel Sidibé
UNAIDS
David Wilson
The World Bank
Steering Committee
Julio Frenk
Richard Marlink
Bruce A. Beal, Robert L. Beal, and Alexander S. Beal
Professor of the Practice of Public Health,
T & G Angelopoulos Professor of Public Health and
international Development, Harvard School of Public Health
and Harvard Kennedy School of Government
Executive Director of the Harvard School of Public Health
AIDS Initiative
Hans-Olov Adami
David Bangsberg
Harvard Medical School
Dan Barouch
Beth Israel Deaconess Medical Center
Barry Bloom
David Bloom
Ronald Bosch
Linda Brady
Allan Brandt
Harvard Faculty of Arts and Sciences,
Dan W. Brock
Clyde Crumpacker
Beth Israel Deaconess Medical Center,
David Cutler
Harvard Faculty of Arts and Sciences,
Harvard Kennedy School of Government, Harvard School of Public Health
Victor DeGruttola
Bruce Donoff
Harvard School of Dental Medicine
Felton Earls
Harvard School of Public Health,
Marilyn Edmunds
April Edrington
Kristin Brown
M. Essex
Harvard University, Harvard School of
Public Health, Botswana–Harvard AIDS
Institute Partnership
Stephen Calderwood
Massachusetts General Hospital
Mansour Safaie Farahani
Paul Campbell
Paul Farmer
Harvard University, Harvard Medical
School, Partners in Health, Brigham and
Women’s Hospital
William Clark
Harvard Kennedy School
of Government
Ellen Cooper
Boston University School of Medicine,
Boston Medical Center
Deborah Cotton
Boston University School of Medicine,
Annals of Internal Medicine
Rajesh Gandhi
Michelle Giuliana
Anne Goldfeld
Sue J. Goldie
Harvard University, Harvard School of
Public Health, Harvard Medical School
Todd Golub
William Graham
Harvard Divinity School, Harvard Faculty
of Arts and Sciences
Robert Greenwald
Harvard Law School
Jerome Groopman
Sofia Gruskin
Jessica Haberer
Daniel Halperin
David Hamer
Boston University School of Public Health
Wafaie Fawzi
Evelynn Hammonds
Harvard Faculty of Arts and Sciences
Sarah Fortune
Robert Hecht
Results for Development Institute
Kenneth Freedberg
Steering Committee | AIDS@30 Engaging to End the Epidemic
5
Steering Committee
Staffan Hildebrand
Face of AIDS Project
Martin Hirsch
Harvard Medical School, Harvard
School of Public Health, Massachusetts
General Hospital
Douglas Hopper
David Hunter
Phyllis Kanki
Edward Ryan
Marc Mitchell
Paul Sax
Joia Mukherjee
Rochelle Scheib
Robert Murphy
Northwestern University
George Seage
Megan Murray
David Shapiro
Gerald T. Keusch
Edward A. Nardell
Tamera Kingston
Marcello Pagano
David Knipe
Judith Palfrey
School of Public Health
Daniel Kuritzkes
Jennifer Leaning
Elinor Levy
Boston University School of Medicine
Judy Lieberman
Shahin Lockman
Elena Losina
Wendy Mariner
Boston University Schools of Public
Health, Law and Medicine
Kenneth Mayer
Harvard Medical School, The Fenway
Institute, Beth Israel Deaconess
Medical Center
6
Kenneth McIntosh
Michael Porter
Harvard University, Harvard
Business School
Alvin Poussaint
Julie Rafferty
Michael Reich
Joseph Rhatigan
William Rodriguez
Eric Rubin
AIDS@30 Engaging to End the Epidemic | Steering Committee
Roger Shapiro
Jonathan Simon
Joseph Sodroski
Ellie Starr
Donald Thea
Rochelle Walensky
Bruce Walker
Ragon Institute of MGH, MIT
and Harvard
Lee-Jen Wei
Rebecca Weintraub
Harvard Medical School, Brigham
and Women’s Hospital
Phill Wilson
Black AIDS Institute
Dyann Wirth
Sub-Committee Co-Chairs
Julio Frenk
T & G Angelopoulos Professor of Public Health and international Development,
Harvard School of Public Health and Harvard Kennedy School of Government
Richard Marlink
Bruce A. Beal, Robert L. Beal, and Alexander S. Beal Professor of the Practice of Public Health,
Executive Director of the Harvard School of Public Health AIDS Initiative
Science, Medicine, and Public Health Co-Chairs
M. Essex
Harvard University, Harvard School of Public Health, Botswana-Harvard AIDS Institute Partnership
Martin Hirsch
Harvard Medical School, Harvard School of Public Health, Massachusetts General Hospital
Bruce Walker
Ragon Institute of MGH, MIT and Harvard
Arts, Advocacy, and Activism Co-Chairs
Paul Farmer
Harvard University, Harvard Medical School, Partners in Health, Brigham and Women’s Hospital
Kenneth Mayer
Harvard Medical School, The Fenway Institute, Beth Israel Deaconess Medical Center
Phill Wilson
Black AIDS Institute
Governance, Leadership, and Financing Co-Chairs
Allan Brandt
Harvard Faculty of Arts and Sciences, Harvard Medical School
Robert Hecht
Results for Development Institute
Rebecca Weintraub
Harvard Medical School, Brigham and Women’s Hospital
Sub-Committee Co-Chairs | AIDS@30 Engaging to End the Epidemic
7
Welcome Message from Staffan
Hildebrand—From Stigma to Hope
As a documentary film producer, I have been documenting global aspects of HIV/AIDS for 25 years. As
a result of my filming, the Face of AIDS film archive gradually has been developed. Our first partner was
the Karolinska Institutet in Stockholm, joined by other academic institutions, organizations, and networks
related to HIV/AIDS. Harvard School of Public Health is among those, and has been an active partner
with the Face of AIDS project for many years.
The result is a unique film archive, containing more than 1,000 hours of unedited film material, shot
by myself and my teams all over the world between 1987 and 2011. Some 50 documentary films have
been produced within the project, many of them produced for presentation at international AIDS
conferences and other AIDS-related events. The goal of the project is to develop the Face of AIDS into
a world-leading digital online film archive, focusing on telling the human story of HIV/AIDS through a
global health perspective.
I am proud to have been part of the planning of the AIDS@30 symposium at Harvard. When the planning
started two and a half years ago, Dean Julio Frenk assigned me to produce a documentary film for the
symposium, based on uniquely selected film sequences from the Face of AIDS archive, as well as new
film material.
When we were discussing the content of the film, Dean Frenk asked me which issues had the strongest
impact on me during my travels around the world. The answer was easy: It was to witness how stigma,
discrimination, and exclusion—which surrounds HIV/AIDS and specific groups of people affected by
the disease—in so many ways have hampered and continue to hamper an effective response to the
epidemic. At the same time, in my filming, I have also been witnessing how many brave and committed
people from all over the world, young and old, have become involved in confronting stigma, discrimination, and exclusion.
Therefore my new documentary film, From Stigma to Hope, will focus on portraying some of those
people. People who stand in the frontline to combat HIV/AIDS, by promoting human rights, sexual
reproductive health and rights, and the emerging arena of global health. These brave people have
been a very strong inspiration in my continuous documentation and many of them have become my
longtime friends. I am happy to invite the participants in the AIDS@30 symposium to meet them in our
film. They will talk about their experiences, but also about how they perceive the future fight against
HIV/AIDS.
I welcome you to watch the film!
Staffan Hildebrand
Producer and Founder, Face of AIDS Project
8
AIDS@30 Engaging to End the Epidemic | Welcome Message from Staffan Hildebrand
Symposium Supporters
The organizers of AIDS@30 would like to thank the following organizations for their generous support.
Lead Supporters
Janssen Global Services
Merck
ViiV Healthcare
Partner Supporters
Gilead Sciences
Harvard University Center for AIDS Research*
MAC AIDS Fund
Sanofi US
Contributing Supporters
Beth V. and Carmine A. Martignetti
Samuel P. Peabody and Elizabeth Peabody, In Memory of Judith Peabody
Additional Support
Multiple offices at Harvard University as well as the following organizations have provided input,
perspective, and support for AIDS@30.
Elizabeth Glaser Pediatric AIDS Foundation
Fenway Community Health Center
The Global Business Coalition
UNAIDS
*An NIH funded program (P30 AI060354), which is supported by the following NIH Institutes and Centers
(NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NCCAM, FIC, NIA, and OAR)
Symposium Supporters | AIDS@30 Engaging to End the Epidemic
9
Day 1 Agenda:
Thursday, December 1, 2011
Time
10
Event
Location
7:45 AM–9:00 AM
Registration and Breakfast
Ground Floor
Lobby
9:00 AM–9:45 AM
Welcome and Opening Remarks
Auditorium
9:45 AM–11:15 AM
SESSION 1: The Future of HIV Prevention
Auditorium
11:15 AM–11:45 AM
Break
Ground Floor
Lobby
11:45 AM–1:15 PM
SESSION 2: International Mobilization and National Leadership
Auditorium
1:15 PM–2:15 PM
Lunch
Ground Floor
Lobby
2:15 PM–3:45 PM
SESSION 3: Global and Local Health Disparities
Auditorium
3:45 PM–4:15 PM
Break
Ground Floor
Lobby
4:15 PM–5:15 PM
Global Premiere: From Stigma to Hope
Auditorium
5:15 PM–5:30 PM
Closing Remarks
Auditorium
5:30 PM–7:00 PM
Reception to Follow at the Conference Center
AIDS@30 Engaging to End the Epidemic | Day 1 Agenda
Day 2 Agenda:
Friday, December 2, 2011
Time
Event
Location
8:00 AM–8:30 AM
Limited Registration,* Breakfast
Ground Floor Lobby
8:30 AM–10:00 AM
SESSION 4: Ending Pediatric AIDS
Auditorium
10:00 AM–10:30 AM
Break
Ground Floor Lobby
10:30 AM–12:00 PM
SESSION 5: The Future of HIV Treatment
Auditorium
12:00 PM–1:00 PM
Lunch
Ground Floor Lobby
1:00 PM–2:30 PM
SESSION 6: Is an HIV Vaccine Possible?
Auditorium
2:30 PM–3:00 PM
Break
Ground Floor Lobby
3:00 PM–4:30 PM
SESSION 7: Funding the Global AIDS Response
Auditorium
4:30 PM–5:00 PM
Closing Remarks
Auditorium
*Registration only required for those who did not attend Day 1
Day 2 Agenda| AIDS@30 Engaging to End the Epidemic
11
Opening and Closing Remarks: Biographies
Video Remarks, Day 1:
President Bill Clinton, served as the 42nd
President of the United States, and is
the Founder of the William J. Clinton
Foundation. The Foundation works
to improve global health, strengthen
economies, promote healthier childhoods, and protect the environment by
fostering partnerships among governments, businesses, nongovernmental organizations (NGOs),
and private citizens to turn good intentions into measurable
results. It works to improve lives through several initiatives,
including the Clinton Health Access Initiative (formerly the
Clinton HIV/ AIDS Initiative), which is helping 4 million people
living with HIV/AIDS access lifesaving drugs. Other initiatives,
like the Clinton Climate Initiative, the Clinton Development
Initiative, and the Clinton Giustra Sustainable Growth Initiative, apply a business-oriented approach worldwide to fight
climate change and develop sustainable economic growth
in Africa and Latin America. And his Clinton Global Initiative
brings together global leaders to devise and implement innovative solutions to some of the world’s most pressing issues.
In addition his Foundation work, President Clinton has joined
with former President George H.W. Bush three times—after
the 2004 tsunami in South Asia, Hurricane Katrina in 2005,
and Hurricane Ike in 2008—to help raise money for recovery
efforts and served as the U.N. Envoy for Tsunami Recovery.
President Clinton was named U.N. Special Envoy for Haiti in
2009 to assist the government and the people of Haiti as they
“build back better” after a series of hurricanes battered the
country in 2008. Following this year’s devastating earthquake,
President Clinton dedicated Clinton Foundation resources to
help with immediate and long-term relief and assistance,
and joined with President George W. Bush to establish the
Clinton Bush Haiti Fund. Additionally, President Clinton serves
as co-chair of the Interim Haiti Recovery Commission with
Prime Minister Bellerive.
Opening Remarks, Day One:
Alan M. Garber, MD, PhD is Provost of
Harvard University, Mallinckrodt Professor of Health Care Policy at Harvard
Medical School, and Professor in the
Harvard Kennedy School Department of Economics. Before coming to
Harvard, he was the Henry J. Kaiser, Jr.
Professor and a Professor of Medicine at
Stanford University, where he also served as founding Director
of the Center for Primary Care and Outcomes Research and
of the Center for Health Policy. From 1986 to 2011 he served
12
as a Staff Physician at the Department of Veterans Affairs
Palo Alto Health Care System. Dr. Garber is a Fellow of the
American College of Physicians and of the Royal College of
Physicians, and an elected member of the American Society
for Clinical Investigation, the Association of American Physicians, and the Institute of Medicine of the National Academy
of Sciences. He serves as a member of the Board on Science,
Technology, and Economic Policy of the National Academies. After graduating summa cum laude from Harvard
College with an AB in Economics in 1976, he earned AM
and PhD degrees in Economics from Harvard University, and
an MD from Stanford University School of Medicine. He was
trained in medicine at Brigham and Women’s Hospital.
Closing Remarks, Day One:
Harvey V. Fineberg, MD, PhD is President
of the Institute of Medicine. He previously served Harvard University as Provost for 4 years and 13 years as Dean of
the School of Public Health. He helped
found and served as President of the
Society for Medical Decision Making
and has been a consultant to the World
Health Organization. His research has included assessment
of medical technology, evaluation of vaccines, and dissemination of medical innovations. At the Institute of Medicine,
he has chaired and served on a number of panels dealing
with health policy issues, ranging from AIDS to new medical
technology. He also served as a member of the Public Health
Council of Massachusetts from 1976–1979, as Chairman of
the Health Care Technology Study Section of the National
Center for Health Services Research from 1982–1985, and as
President of the Association of Schools of Public Health from
1995–1996. He is the author or co-author of numerous books
and articles on subjects ranging from HIV prevention to medical education. Dr. Fineberg holds four degrees from Harvard,
including the MD and PhD in Public Policy.
Closing Remarks, Day One:
Jeffrey S. Flier, MD is the 21st Dean of
the Faculty of Medicine at Harvard
University, appointed in July 2007.
Flier, an endocrinologist and one of
the country’s leading investigators on
the molecular causes of obesity and
diabetes, is also the Caroline Shields
Walker Professor of Medicine at Harvard
Medical School. Previously he had served as Harvard Medical School Faculty Dean for Academic Programs and Chief
AIDS@30 Engaging to End the Epidemic | Opening and Closing Remarks: Biographies
Academic Officer for Beth Israel Deaconess Medical Center
(BIDMC), a Harvard teaching affiliate. Dean Flier’s research
has produced major insights into the molecular mechanism
of insulin action, the molecular mechanisms of insulin resistance in human disease, and the molecular pathophysiology
of obesity. He first joined the HMS faculty in 1978, as Chief of
the Diabetes Unit at Beth Israel Hospital, becoming Chief of
the Endocrine Division in 1990 and, in 2001, Chief Academic
Officer for the merged Beth Israel Deaconess Medical Center.
Flier has authored over 200 scholarly papers and reviews and
has held many editorial positions. He is a fellow of the Institute of Medicine of the National Academy of Sciences, the
American Association for the Advancement of Science, and
the American Academy of Arts and Sciences.
Opening Remarks, Day One;
Closing Remarks, Day Two:
Julio Frenk, MD, MPH, PhD is Dean of
Faculty at the Harvard School of Public
Health and T & G Angelopoulos Professor of Public Health and International
Development, a joint appointment between the Harvard Kennedy School of
Government and HSPH that he has held
since January 2009. Dr. Frenk served
as the Minister of Health of Mexico from 2000 to 2006, where
he introduced universal health insurance. He has also held
leadership positions at the National Institute of Public Health
of Mexico, the Mexican Health Foundation, the World Health
Organization, the Bill & Melinda Gates Foundation, and the
Carso Health Institute. He is a member of the Institute of
Medicine, the American Academy of Arts and Sciences, and
the National Academy of Medicine of Mexico. In September
of 2008, Dr. Frenk received the Clinton Global Citizen Award
for changing “the way practitioners and policy makers across
the world think about health.”
Film Producer:
Staffan Hildebrand, a Swedish documentary film producer, was based in
Bangkok between 1971–75 as a young
Far East correspondent for the National
Swedish TV News, covering the end of
the Vietnam War. In the 1980s he directed several full-length feature movies targeting a young audience, based
on true stories. All of them became box office hits. In 1987 he
started the Face of AIDS film documentation project in close
collaboration with the Karolinska Institutet, Stockholm—a
collaboration that continues. For 25 years he has continuously
documented global and local aspects of HIV/AIDS on film.
The result is the unique Face of AIDS film archive, containing
more than 1,000 hours of unedited and edited film material.
As part of his project, Mr. Hildebrand has produced HIV/AIDS
related documentaries for the International AIDS Society
(IAS), WHO and UNAIDS, Geneva, Canadian International
Development Research Council, (IDRC), U.S. National Institute
of Allergy and Infectious Diseases, (NIAID), Bethesda, Institute
of Human Virology, Baltimore, Southern Africa AIDS Trust
(SAT), Johannesburg, Discovery Channel USA, Channel Five
Australia, Karolinska Institutet and the Swedish Ministry of
Foreign Affairs, and many more. The film he produced for
Harvard’s AIDS@30 Symposium, From Stigma to Hope,
contains film material from the Face of AIDS film archive
as well as new material.
Opening Remarks, Day One;
Closing Remarks, Day Two:
Richard Marlink, MD is a medical oncologist and a Professor in the Department
of Immunology and Infectious Diseases
at the Harvard School of Public Health.
He also serves as the Executive Director
of the Harvard School of Public Health
AIDS Initiative and is the Senior Advisor for Medical and Scientific Affairs at
the Elizabeth Glaser Pediatric AIDS Foundation. Since 1985,
Dr. Marlink has directed HIV/AIDS-related research, training
and health systems strengthening in Botswana, Brazil, Congo,
Cote d’Ivoire, Puerto Rico, Senegal, South Africa, Tanzania,
Thailand and Zambia. With Max Essex, he helped create the
Botswana-Harvard AIDS Institute Partnership, officially established in 1996. Under his direction, the Partnership and the
Botswana Ministry of Health launched the KITSO AIDS Training
Program in 1999, which helps train all cadres of healthcare
providers, and is now Botswana’s national HIV/AIDS training program. At Elizabeth Glaser Pediatric AIDS Foundation,
Dr. Marlink is the Principle Investigator for Project HEART, the
Foundation’s five-country PEPFAR program in Africa. This project alone has enrolled over a million people living with HIV
into clinical care, with over 500,000 of those placed on antiretroviral treatment and over 450,000 pregnant women living
with HIV placed on treatment to prevent HIV transmission to
their offspring. Dr. Marlink is Editor-in-Chief of the Foundation’s
three-volume text, From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings,
involving 235 authors from over 60 institutions internationally.
Opening and Closing Remarks: Biographies | AIDS@30 Engaging to End the Epidemic
13
Session 1: The Future of HIV Prevention
9:45 AM–11:15 AM
Recent studies have shown antiretroviral therapy can greatly reduce the
chance of transmitting HIV. New evidence also suggests pre-exposure prophylaxis (PrEP) may be an effective prevention intervention, especially among
high-risk populations. How will these historic scientific advances change the
approach HIV prevention?
Key Questions:
s #AN THE USE OF ANTIRETROVIRAL DRUGS FOR PREVENTION BE COSTEFFECTIVE
s 7HAT POPULATIONS SHOULD BE PRIORITIZED
s 7HAT ARE THE BIOMEDICAL IMPLICATIONS PARTICULARLY REGARDING THE POSSIBILITY OF INCREASED
drug resistance?
s 'IVEN THE PROMISE OF USING ANTIRETROVIRAL DRUGS FOR PREVENTION WHAT ROLE WILL BEHAVIORAL
interventions play in the future?
Perspective:
Wafaa El-Sadr, MD, MPH is Professor of Epidemiology and Medicine at Columbia University’s Mailman School of Public
Health (MSPH) and College of Physicians and Surgeons, and Director of ICAP, a large center she established at MSPH
that addresses key global health challenges. She also leads the Global Health Initiative at MSPH. She is a recognized
leader in global health with interests in HIV, tuberculosis maternal/child health, capacity building, and health systems
strengthening. Her work bridges a commitment to local and global public health and she has a deep appreciation of
the breadth of issues needed to transform the health of populations. Through ICAP, large scale programs have been
established in sub Saharan Africa that link research, education, training, and practice with a focus on HIV, related
conditions, and health system strengthening. Through her leadership of the Global Health Initiative, great strides have
been made to strengthen linkages and synergies between the many diverse endeavors by the faculty of the school.
Her work and scholarship have appeared in many leading journals and she was named a MacArthur Fellow in 2008.
Moderator:
M. Essex, DVM, PhD is the Lasker Professor of Health Sciences at Harvard University, Chair of the Harvard School of
Public Health AIDS Initiative, and Chair of the Botswana–Harvard AIDS Institute in Gaborone, Botswana. He was one of
the first to link animal and human retroviruses to immunosuppressive disease. For this he shared the Lasker Award, the
highest medical research award given in the United States, with Gallo and Montagnier in 1986. With his student, T. H.
Lee, he was also the first to identify gp120, the surface protein of HIV-1 that is used for blood screening and diagnosis
of AIDS, as well as various vaccine designs. He has received numerous other awards and nine honorary degrees, and
has published over 580 papers and 11 books, the latest being Saturday Is for Funerals. His current research includes
comprehensive “test-and-treat” approaches to controlling the HIV epidemic, molecular epidemiology, the role of
host genetic factors, and chemoprophylaxis, with emphasis on southern Africa.
14
AIDS@30 Engaging to End the Epidemic | Session 1: The Future of HIV Prevention
Participants:
Deborah Birx, MD has been Director of Division of Global HIV/AIDS in CDC’s Center for Global Health since 2005.
Dr. Birx oversees all of CDC’s global HIV/AIDS activities in support of the President’s Emergency Plan for AIDS Relief
(PEPFAR), which includes nearly 400 staff at headquarters, over 1,200 staff in the field, and more than 43 country
offices in Africa, Asia, Caribbean, and Latin America. She has had decades of international experience in the field
of HIV/AIDS. Beginning her career in 1985 as a trained clinician in immunology, Dr. Birx focused on HIV/AIDS vaccine
research. From 1985–1989 she served as the Assistant Chief of the Allergy Immunology Service at Walter Reed Army
Medical Center, earning the U.S. Meritorious Service Medal for her leadership in refining, validating, and standardizing cell-mediated immunity testing in HIV-infected patients. She was also recognized with the U.S. Meritorious Service
Medal for her ground-breaking work in organizing and implementing a vaccine therapy efficacy trial from 1990–1995.
She served as the Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research
from 1996–2005 and received the Legion of Merit award for her leadership.
Robert (Bob) Grant, MD, MPH is a Senior Investigator at the Gladstone Institute of Virology and Immunology and
Associate Professor of Medicine at the University of California San Francisco. He has more than 26 years experience
with AIDS clinical care and research, which includes 4 years in leading roles in epidemiological studies in
San Francisco and Uganda, followed by a fellowship in Molecular Medicine, after which he started the Gladstone/
UCSF Laboratory of Clinical Virology in 1997 and the Gladstone Laboratory of Molecular Evolution in 2000. Dr. Grant
is currently the protocol chair for the Pre-Exposure Prophylaxis (or PrEP) Initiative study, which involves use of antiviral
agents to block transmission of HIV-1 to highly exposed persons, in addition to standard prevention care. This global
clinical trial is sponsored by the U.S. NIH and has sites in Peru, Ecuador, Brazil, United States, South Africa, and Thailand.
Dr. Grant’s laboratory is also interested in HIV-1 superinfection, drug resistance, and mutagenesis. Understanding
when superinfection occurs, and when it does not, could provide clues to protective immunity that would guide
HIV vaccine development.
Sharon L. Hillier, PhD is Professor and Vice Chair for Faculty Affairs, and Director of Reproductive Infectious Disease
Research in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh
School of Medicine. She holds secondary appointments in the Department of Microbiology and Molecular Genetics
and with the Clinical and Translational Science Institute, and is a Senior Investigator at the University of Pittsburghaffiliated Magee-Womens Research Institute. Dr. Hillier is an internationally recognized microbiologist whose work is at
the intersection of women’s health and HIV prevention. She is Principal Investigator for the Microbicide Trials Network
and for an NIH-funded project looking at alternative formulations for microbicides. Dr. Hillier’s research has focused on
understanding both the preventive and causative roles that certain microorganisms in the vagina have with respect
to genital tract infections, sexually transmitted infections, including HIV, and pre-term birth, and on the evaluation of
vaginal microbicides. Dr. Hillier has received numerous prestigious awards, and in 2010 was named to a two-year term
as chair of the NIH Office of AIDS Research (OAR) Advisory Council.
Nancy Padian, PhD, MPH is an internationally recognized leader in the epidemiology and prevention of sexually transmitted infections (STIs) including HIV. For the last 25 years, she has led numerous initiatives dedicated to improving the
health status of women and girls around the world by conducting research on HIV/AIDS and STIs, reproductive health,
domestic violence, gender and economic inequities, contraceptive technologies, and female-initiated methods of
HIV prevention. She is a senior technical advisor at the Office of the Global AIDS Coordinator (PEPFAR) and a faculty
member at the University of California, Berkeley in the Department of Epidemiology. Dr. Padian is an elected member
of the Institute of Medicine, the American Epidemiology Society, and the International Society for Sexually Transmitted
Disease Research. She frequently consults for UNAIDS, WHO and the U.S. National Institutes of Health (NIH).
John C. Pottage Jr., MD is Chief Scientific and Medical Officer of ViiV Healthcare. He oversees R&D, Regulatory,
Safety and Medical Affairs. Dr. Pottage is the former SVP, Infectious Diseases Medicine Development Centre for GSK.
He previously held senior positions at Vertex Pharmaceuticals and Achillion Pharmaceuticals, where he helped lead
a successful IPO in 2006 and led the HIV and HCV development programs. Before joining the pharmaceutical industry, Dr. Pottage was Associate Professor of Internal Medicine in the Section of Infectious Diseases at Rush Medical
College in Chicago. While at Rush, he was Director of the Outpatient HIV Centre. Dr. Pottage is board certified in both
Internal Medicine and Infectious Disease. He is the author of more than 50 peer-reviewed medical articles as well as
the author of several chapters in Infectious Disease textbooks.
Session 1: The Future of HIV Prevention| AIDS@30 Engaging to End the Epidemic
15
Session 2: International Mobilization
and National Leadership
11:45 AM–1:15 PM
This past decade, PEPFAR, the Global Fund, and other donor organizations have
pumped billions of dollars into the global AIDS response. The scale-up has saved
millions of lives and established the AIDS response as a global priority. Amid a
rapidly changing funding landscape, and efforts to transfer responsibility from
donors to country leaders, how will national leaders sustain the AIDS response?
Key Questions:
s 7HAT IS THE MOTIVATION FROM EXTERNAL DONORS TO SHIFT RESPONSIBILITY TO INDIVIDUAL COUNTRY LEADERS
s (OW CAN HEALTH SYSTEMS BE STRENGTHENED TO BOLSTER THE !)$3 RESPONSE WHILE ALSO ADDRESSING
neglected diseases?
s 7HERE SHOULD ONE LOOK FOR EXAMPLES OF SUCCESSFUL NATIONAL LEADERSHIP (OW HAVE THESE COUNTRY
leaders sustained viable AIDS responses?
s )S IT POSSIBLE FOR COUNTRY LEADERS TO CREATE SUSTAINABLE RESPONSES WHILE STILL RELYING ON EXTERNAL FUNDS
s (OW SHOULD hSUSTAINABILITYv BE MEASURED
Perspective:
Mariângela Simão, MD, MSc joined UNAIDS in July 2010 from the Ministry of Health in Brazil, where she had worked
since 2006 as the Director of the Department of Sexually Transmitted Diseases and AIDS. She has worked in the Brazilian public health system since 1982, from the primary health care level to a series of managerial positions throughout
the years. As a public health professional at municipal, state and national levels, she played an active role in the decentralization of the national health system, acquiring extensive experience in health system strengthening. She has
also served on the boards of a number of organizations and government committees related to public health and
HIV. Heading the National Sexually Transmitted Diseases/AIDS Department (including Viral Hepatitis from 2009), she
had the responsibility of overseeing and implementing the national Sexually Transmitted Diseases/AIDS/Viral Hepatitis
policies, including universal and free of charge access to treatment, care and comprehensive prevention programs.
She currently works at UNAIDS Secretariat in Geneva, heading the Prevention, Vulnerability and Rights Division.
Dr. Simão attended medical school in Brazil, with degrees in Paediatrics and Public Health, and MSc in Mother and
Child Health (UK).
Moderator:
Phyllis Kanki, DVM studies the pathogenesis and molecular epidemiology of HIV in Africa. She has led AIDS research
programs in Senegal for more than 20 years, where her research focused on identification and reduced transmission
of HIV-2, cross protection between HIV-2 and HIV-1, and the genetics, pathology biology and epidemiology of different HIV-1 genotypes. From 2000–2005, Dr. Kanki directed the AIDS Prevention Initiative in Nigeria (APIN), a program she
created with a grant from the Gates Foundation. Since 2004, Dr. Kanki has served as the principal investigator for the
U.S.-funded Harvard PEPFAR program, which provides training, capacity building and targeted evaluation in three
partner countries (Nigeria, Tanzania, Botswana), with the goal of scaling up access to antiretroviral therapy (ART). The
program has now provided ART to over 155,000 patients in the three countries with significant operational research
that contributes to the success of the program. She directs HSPH’s partnership with five universities in the Medical Education Partnership in Nigeria. Dr. Kanki has provided mentoring for more than 30 doctoral students and fellows from
from African Countries and the US.
16
AIDS@30 Engaging to End the Epidemic | Session 2: International Mobilization and National Leadership
Participants:
Elly Katabira trained as a medical doctor at Makerere University and as a physician, specializing in Neurology at the
University of Manchester (UK). Since his return to Uganda in 1985, Dr. Katabira has worked extensively in the field of
care and support for people living with HIV. He is Clinical Advisor at the AIDS Clinic in Mulago Hospital and at the
Infectious Diseases Institute of Makerere University College of Health Sciences. In 1990, he was recognized as a World
AIDS Foundation International Scholar. The author of more than 200 published scientific articles and abstracts, Dr.
Katabira was elected a member of IAS Governing Council in the African Region in 2000. Since then he has actively
participated in many IAS activities, including Co-Chair of the IAS-Industry Liaison Forum and Co-Editor of the Journal
of the International AIDS Society. Dr. Katabira has undertaken several consultancies on HIV and AIDS care and support for UNAIDS and WHO, as well as for Family Health International. He is co-founder of The AIDS Support Organization, serving as their Medical Advisor since 1987, and is a founding member of the Academic Alliance of AIDS Care
and Prevention in Africa.
Festus Mogae was President of Botswana from 1998–2008 and is Chairman of the Champions for an HIV-Free Generation. As President, he earned international praise for his efforts to combat the HIV/AIDS epidemic in Botswana, one
of the countries hit hardest by the disease. He was one of the first heads of state in the world to be publicly tested
for HIV. Under his administration, Botswana became the first country in Africa to provide free anti-retroviral therapy
to citizens most in need. In 2004, he introduced routine “opt-out” HIV testing, which has dramatically increased the
number of people who know their HIV status. Botswana also has made impressive strides in preventing mother-to-child
HIV transmission and caring for children orphaned by AIDS. His Excellency Mogae studied economics at Sussex and
Oxford universities in the United Kingdom, and worked in various civil service posts throughout his career, including
Minister of Finance and Development Planning (1989–92) and Vice President (1992–98). He has received a number of
international awards, including the 2008 Mo Ibrahim Prize for Achievement in African Leadership and the Grand Cross
of the Legion d’honneur in France.
Anders Nordström, MD is Ambassador for HIV/AIDS in Sweden’s Ministry for Foreign Affairs, a post he has held since
August 2010, and serves on the boards of UNAIDS, The Global Fund to Fight AIDS, Tuberculosis and Malaria, GAVI, and
PMCH. As a medical doctor from the Karolinska Institut in Sweden, Dr. Nordström has a background that combines
development experience in the field, national and international health policy and planning, and strategic leadership.
His first international assignments were with the Swedish Red Cross in Cambodia and the International Committee of
the Red Cross in Iran. He worked initially for the Swedish International Development Cooperation Agency for 12 years,
including three years as Regional Health Advisor in Zambia and four years as Head of the Health Division in Stockholm. During 2002, Dr. Nordström was the Interim Executive Director for the Global Fund to Fight AIDS, Tuberculosis and
Malaria and, in 2003, took office as Assistant Director-General at WHO for General Management. He was the Acting
Director-General of WHO from May 2006 until January 2007, when he was appointed Assistant Director-General for
Health Systems and Services. From January 2008 until June 2010 Dr. Nordström served as Director-General for the
Swedish International Agency for Development Cooperation.
Suniti Solomon, MD is Director of the Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE), a nonprofit organization she founded in 1993 that offers HIV and sexuality education for adolescents and youth, voluntary
counseling and testing services, and outpatient and inpatient services for over 15,000 persons living with HIV. It has an
international reputation as a premier medical and behavioral research center. Dr. Solomon has been working in this
field since her team first detected HIV in 1986. She serves as a scientific member on several national committees and
has published extensively on HIV epidemiology, prevention, care and support, biomedical research, research ethics,
and gender issues. She holds an MD from Madras University and trained in pathology in the United Kingdom and the
United States. She has received two Lifetime Achievement Awards for her work with AIDS. She was also awarded an
honorary doctoral degree in 2006 from Brown University and a Fellow of the Academy, from National Academy of
Medical Science, New Delhi in 2010.
Session 2: International Mobilization and National Leadership | AIDS@30 Engaging to End the Epidemic
17
Session 3: Global and Local Health Disparities
2:15 PM–3:45 PM
Over the last several decades tremendous advances have been made,
particularly in recent years with the scaling-up of antiretroviral treatment and
new advances in HIV prevention. Some say the medical tools to end the
epidemic now exist. Yet, all the progress is set against the backdrop of shrinking
resources and widening health disparities. How should significant medical
breakthroughs be implemented, while assuring that those without resources,
including those in the United States, are not left behind?
Key Questions:
s (OW CAN PUBLIC HEALTH LEADERS EFFECTIVELY ADDRESS STIGMA AND DISCRIMINATION IN PARTICULAR
among high-risk populations?
s 7HAT ROLE ARE COMMUNITY HEALTH CENTERS PLAYING IN REACHING UNDERSERVED POPULATIONS AND
how are local HIV/AIDS services adapting to the global economic slowdown?
s $OES THE 5NITED 3TATES .ATIONAL ()6!)$3 3TRATEGY SUFlCIENTLY ADDRESS THE NEEDS OF HIGHRISK
populations, such as black gay men and MSM?
s (OW HAVE COMMUNITIES AROUND THE WORLD ADDRESSED DISPARITIES AND WHAT HAVE BEEN THE MOST
effective approaches?
Perspective:
Paul Farmer, MD, PhD is a Founding Director of Partners In Health (PIH), an international non-profit organization that
provides direct health care services, research and advocacy on behalf of those who are sick and living in poverty.
A medical anthropologist and physician, Dr. Farmer is the Kolokotrones University Professor at Harvard University, Chair
of Harvard Medical School’s Department of Global Health and Social Medicine, and Chief of the Division of Global
Health Equity at Brigham and Women’s Hospital in Boston. He served ten years as medical director of a charity hospital, L’Hôpital Bon Sauveur, which he helped found in rural Haiti and, since 2009, has been a UN Deputy Special Envoy
for Haiti, under Special Envoy Bill Clinton. His work focuses on community-based treatment strategies for infectious
diseases in resource-poor settings, health and human rights, and the role of social inequalities in determining disease
distribution and outcomes. Among his notable awards are the Conrad N. Hilton Humanitarian Prize (2005) and MacArthur Foundation “genius grant” (1993), which he donated to PIH to start a research program, the Institute for Health
and Social Justice.
Perspective:
Kenneth H. Mayer, MD is a Visiting Professor of Medicine at Harvard Medical School and Attending Physician at Beth
Israel Deaconess Medical Center. He previously was Professor of Medicine & Community Health at Brown University
and Director of the Brown University AIDS Program. He is the Medical Research Director of the Fenway Community
Health Center in Boston, where he has conducted studies of the natural history and transmission of HIV since 1983.
While doing his fellowship in Infectious Diseases at Harvard Medical School, Dr. Mayer was one of the first clinical
researchers in Boston to see patients with AIDS and HIV infection. He has published extensively on AIDS, specifically on
topics concerning the natural history, behavioral epidemiology, transmission variables, and public policy aspects of
the epidemic. He is now a Principal Investigator of the NIH HIV Prevention Trials Network (HPTN) and Microbicide Trials
Network (MTN) and co-Principal Investigator of the NIH HIV Vaccine Trial Network (HVTN). He has been on the Board
of Directors of amFAR, HIVMA, and GLMA, and is a member of the Governing Council of the International AIDS
Society. He is a special topics editor for Clinical Infectious Diseases and Associate Editor of AIDS Patient Care and
STDs. He has co-authored more than 450 original publications and co-edited 5 texts.
18
AIDS@30 Engaging to End the Epidemic | Session 3: Global and Local Health Disparities
Moderator:
Phill Wilson is President and CEO of the Black AIDS Institute, whose mission is to stop the AIDS pandemic in Black
communities by engaging and mobilizing Black institutions and individuals in efforts to confront HIV. Prior to founding the Institute, Mr. Wilson was the AIDS Coordinator for the City of Los Angeles (1990 to 1993) and Director of Policy
and Planning at AIDS Project Los Angeles (1993 to 1996). He was the coordinator of the International Community
Treatment and Science Workshop at the 12th, 13th, 14th, and 15th International AIDS Conferences and was a member of the U.S. delegation to the 1994 World AIDS Summit in Paris. He has worked extensively on HIV/AIDS policy,
research, prevention and treatment issues in Russia, Latvia, the Ukraine, the UK, Holland, Germany, France, Mexico,
South Africa, Zimbabwe, Zambia, Tanzania, India, and Botswana. Mr. Wilson co-founded the National Task Force
on AIDS Prevention, as well as many other AIDS service and community-based organizations, including the Chris
Brownlie Hospice, the AIDS Healthcare Foundation, the National Minority AIDS Council, and the Los Angeles County
Gay Men of Color Consortium.
Participants:
Dázon Dixon Diallo, MPH is Founder and President of SisterLove, Incorporated, established in 1989, the first women’s
HIV/AIDS organization in the southeastern United States. She is also adjunct faculty in women’s health at Morehouse
School of Medicine’s Masters of Public Health Program in Atlanta, Georgia. Ms. Diallo has been engaged in HIV/AIDS
and women’s human rights for more than 27 years. She is a founding board member of SisterSong Women of Color
Reproductive Justice Collective, chairs the Fulton County HIV/AIDS Services Planning Council and the Steering Committee of the Global Campaign for Microbicides, and co-chairs the Community Advisory Board of the HOPE Clinic,
Emory University’s HIV Vaccine and Microbicides Research Center. She developed a prevention intervention that is
now a part of the CDC’s National Compendium of Evidenced-based HIV Prevention Interventions and established
the first transitional housing program for HIV-positive women and children. In 2001, Dixon Diallo opened a SisterLove
program office in Mpumalanga, a rural South African Province near Johannesburg, with a focus on capacity building and sustainable development for local, women-led HIV/AIDS organizations.
Jean William Pape, MD is Professor of Medicine at Weill Cornell Medical College in New York and Director of Les
Centres GHESKIO, Port-au-Prince, Haiti. Dr. Pape completed his Medicine and Infectious Diseases training at Cornell,
and joined the Cornell faculty prior to returning to his native Haiti in 1980. Subsequently, he defined the etiology of
diarrhea in infants and introduced oral rehydration therapy into Haiti, with a decrease in the hospital infant mortality
rate from 40%, to less than 1% within one year. In 1982, Dr. Pape and colleagues founded the “Haitian Study Group
on Kaposi’s sarcoma and opportunistic infections (GHESKIO),” the first institution in the world dedicated to the fight
against AIDS. He assumed an international leadership role and has been unrelenting in his efforts to implement programs for the prevention and control of AIDS and tuberculosis in Haiti and other resource-poor countries. Dr. Pape is
the recipient of many national and international awards including the French Legion d’honneur (2002), election to
the U.S. Institute of Medicine of the National Academy of Sciences (2003), the National Alive Treasure of Haiti award,
the Gates 2010 award and the Clinton Global Initiative award.
Jorge Saavedra, MD, MPH is Global Ambassador at the AIDS Healthcare Foundation. From 2003 to 2009, he was the
Head of the National AIDS Program of Mexico (CENSIDA), where he led the successful effort to provide access to
lifesaving antiretroviral therapy to all Mexican citizens living with HIV/AIDS through the national health system. He
founded the first ambulatory care clinic in Mexico in 2000, and from 2005 to 2009 he founded 52 new sites based on
that Clinica-Condesa model. Dr. Saavedra has written several publications related to costs and financing of HIV in
Latin America and Mexico and is the recipient of several national, regional and international awards and recognitions. An outspoken advocate on HIV/AIDS prevention and treatment issues, Dr. Saavedra designed and led the
first official government-approved media campaign to promote the use of condoms in Mexico. He has also been
out front with the need to address stigma, discrimination and homophobia in the fight against HIV/AIDS in Mexico
and around the world. He launched an official anti-machismo education campaign as well as a first governmentendorsed anti-homophobia campaign in Mexico.
Session 3: Global and Local Health Disparities | AIDS@30 Engaging to End the Epidemic
19
Session 4: Ending Pediatric AIDS
8:30 AM–10:00 AM
Thirty years after the first AIDS diagnosis, it is medically possible to prevent
virtually all new HIV infections in infants and young children. However, mother-tochild transmission of HIV is still a significant problem in many regions of the world,
particularly in sub-Saharan Africa. How can the elimination of pediatric AIDS
become a reality?
Key Questions:
s 7HAT WILL IT TAKE TO ACTUALLY END PEDIATRIC !)$3 WORLDWIDE 7HAT BARRIERS MUST BE ADDRESSED TO
ensure that new medical and scientific advances are put into action?
s (OW SHOULD THE SPECIAL NEEDS OF CHILDREN BE PRIORITIZED IN THE RESPONSE TO THE EPIDEMIC
s (OW HAVE COUNTRY LEADERS AND LOCAL PUBLIC HEALTH LEADERS EFFECTIVELY INCREASED PREVENTION OF
mother-to-child-transmission (PMTCT)?
s 7HILE THERE IS THE MEDICAL ABILITY TO PREVENT VIRTUALLY ALL NEW ()6 INFECTIONS HOW MUCH WILL IT COST
and where does financial responsibility fall?
s 7HAT ACTIONS SHOULD MOTHERS TAKE TO PREVENT MOTHERTOCHILDTRANSMISSION
Perspective:
Florence Allen, also known as Florence Ngobeni, is from South Africa, and an ambassador of the Elizabeth Glaser
Pediatric AIDS Foundation, the Southern African Liaison Ambassador for Orange Babies in Amsterdam, and a member of International Community of Women Living with HIV/AIDS. Florence has been an activist since 1997 on the
forefront in South Africa and around the world fighting for girls and young women’s sexual and reproductive rights,
access to HIV treatment, and prevention of mother-to-child-transmission. She does consulting and training with HIV
SA on community/workplace projects and works with major development agencies and businesses on implementing
HIV policies on testing and counseling. She participated in research on the availability of HIV/AIDS services for young
girls and women with the International Planned Parenthood Federation. She has a community development and
counseling diploma, HIV and AIDS management certificates, and certificates in management of HIV/AIDS from Johns
Hopkins (USA), New Jersey Medical School (USA), University of South Africa, and Education Technikon Witwatersrand.
Her activist work has won her numerous awards, including the Africa Heroes Award, 2005–2006 for community development and advocacy by the University of Ohio (USA).
Moderator:
Charles Lyons is President and Chief Executive Officer of the Elizabeth Glaser Pediatric AIDS Foundation. His professional emphasis is on children’s welfare, HIV/AIDS, and global development. Prior to joining the Foundation in 2010, Mr.
Lyons was Director of Special Initiatives in the Global Development Program at the Bill & Melinda Gates Foundation,
where he led a team dedicated to global poverty reduction. Prior to that, he spent more than 20 years in increasingly
prominent roles with the United Nations Children’s Fund (UNICEF), including Program Officer for UNICEF Mozambique;
Chief of Staff to the Executive Director at UNICEF headquarters; and President and CEO of the U.S. Fund for UNICEF. A
longtime advocate for global health, he is a member of the Human Rights Watch Health and Human Rights Advisory
Committee, and worked from its inception to develop the Global Alliance for Vaccines and Immunization (GAVI),
serving on the board of the GAVI Fund and chairing its executive committee from 2004 to 2006. In 2011, he was appointed by President Obama as U.S. Alternate Representative to the UNICEF Executive Board.
20
AIDS@30 Engaging to End the Epidemic | Session 4: Ending Pediatric AIDS
Participants:
Elaine Abrams, MD is Senior Research Director at the ICAP and Professor of Pediatrics and Epidemiology at the
Columbia University College of Physicians & Surgeons and the Mailman School of Public Health in New York City. She
began her career as a pediatrician at Harlem Hospital in New York City just as the first cases of pediatric HIV infection
were being identified. Over the next 15 years Dr. Abrams was responsible for treating more than 1,500 HIV-exposed
and infected children and their families. She was Director of the hospital’s Family Care Center and the principal
investigator for several longstanding research collaborations and clinical trials focusing on prevention of mother-tochild HIV transmission and pediatric HIV treatment. As the scope of the pediatric epidemic in the United States has
diminished, Dr. Abrams has shifted her focus to high HIV prevalence settings, primarily in Sub Saharan Africa. She is
responsible for pediatric and PMTCT programming in 12 African countries where ICAP is supporting HIV prevention,
care and treatment services. She chairs the NIH-funded IMPAACT Network’s Primary Therapy Scientific Committee
and is a member of both the WHO and USPHS guidelines committees for pediatric HIV treatment and for prevention
of mother-to-child transmission.
Angela Mushavi, MBChB is the National PMTCT (Preventing Mother-to-Child Transmission) and Pediatric HIV Care and
Treatment Coordinator in the Ministry of Health and Child Welfare in Zimbabwe. Dr. Mushavi chairs the National PMTCT
Partnership Forum and provides technical leadership in scaling-up implementation of PMTCT and Pediatric HIV Care
and Treatment as well as in identifying in priority areas for operational research. From 2007–2009 she worked with CDC
Namibia as a PMTCT Technical Advisor to the Ministry of Health and Social Services. As a member of the U.S. team in
Namibia, she actively participated in the revision of HIV and AIDS policy and guidelines. From 2004–2007, she was the
Paediatrician running the Paediatric ART Clinic at Katutura State Hospital, a referral hospital in Windhoek, Namibia.
Before that, she was Head of Division of the Harare Children’s Hospital in Zimbabwe and a consultant in charge of a
firm delivering clinical care to children. A member of the Southern Africa HIV Clinicians Society and a steering committee member of the African Network for the Care of Children Affected by HIV/AIDS (ANECCA), Dr. Mushavi contributed to the publication of the ANECCA Handbook on Paediatric AIDS in Africa.
Joy Phumaphi is the Executive Secretary of the African Leaders Malaria Alliance. Her former positions include Vice
President, Human Development Network at the World Bank; Assistant Director-General, Family and Community Health
and Director-General’s Representative on Gender Equality at the World Health Organization. She has also served
as the Minister of Health in Botswana. Joy is a distinguished Africa American Institute Fellow and is a member of the
Global Leaders Council for Reproductive Health, the Gates Foundation Advisory Panel for Global Health and The
Global Health Council. Joy also serves as a trustee of the Children’s Investment Fund Foundation.
Session 4: Ending Pediatric AIDS| AIDS@30 Engaging to End the Epidemic
21
Session 5: The Future of HIV Treatment
10:30 AM–12:00 PM
Combination antiretroviral treatment for HIV/AIDS has paved the way for a
dramatic reduction in morbidity and mortality and the change of such treatment
in developing countries is now promising. The future discovery of new agents—
and new classes of agents—is highly dependent on investments from the private
sector and the pharmaceutical industry. However, the risks for such investments
are high, given the costs of creating therapies for populations that, for the most
part, cannot afford them. How will the development and distribution of affordable HIV therapeutics be sustained?
Key Questions:
s 7HAT NEW AGENTS AND DELIVERY METHODS WILL BE AVAILABLE TO HELP ADDRESS PROBLEMS OF ACCESS
and economic disparities?
s 7HAT ROLE WILL THE PRIVATE SECTOR AND PRIVATEPUBLIC PARTNERSHIPS PLAY IN THE FUTURE DEVELOPMENT
and distribution of HIV therapeutics??
s (OW SHOULD INNOVATION AND THE DEVELOPMENT OF A VIABLE PHARMACEUTICAL INDUSTRY BE ENCOURAGED
within developing countries?
s 7ILL IT BE POSSIBLE TO CURE ()6 INFECTION WITH NEW THERAPIES
Perspective:
Jeffrey S. Murray, MD, MPH is Deputy Director for the Division of Antiviral Products (DAVP), U.S. Food and Drug
Administration, Center for Drug Evaluation and Research (CDER). He has worked in the Division in various capacities
for 19 years. At DAVP, Dr. Murray has reviewed and approved applications for numerous HIV drugs, influenza drugs,
and applications for hepatitis B and C products. He has co-authored FDA guidance documents in HIV drug development, development of HIV drugs for the President’s Emergency Plan for AIDS Relief (PEPFAR), and the development
of drugs for the treatment of Influenza and Chronic Hepatitis C. Dr. Murray received his MD from The Ohio State
University, also in Columbus, and his MPH in Epidemiology and Biostatistics from George Washington University in
Washington, DC. He completed his internship, residency and chief residency in Internal Medicine at Riverside
Methodist Hospitals in Columbus, followed by a fellowship in Infectious Diseases (1990–1992) at the University of Cincinnati Medical Center in Cincinnati, Ohio. Dr. Murray is board certified in Internal Medicine and Infectious Diseases.
Moderator:
Martin S. Hirsch, MD is Professor of Medicine at the Harvard Medical School, Professor of Infectious Diseases and
Immunology at the Harvard School of Public Health, and a Senior Physician at the Massachusetts General Hospital.
He is also the Editor in Chief of the Journal of Infectious Diseases. For over 40 years, Dr. Hirsch has worked in virology
research. He has also trained many of the current leaders in virology and AIDS research. His group was the first to
show that HIV could be isolated from both male and female genital secretions, as well as from the central nervous
system. He conducted the first studies of antiretroviral drug combinations in vitro, and has extended these efforts into
pioneering clinical trials of promising antiretroviral combination strategies against HIV/AIDS. Dr. Hirsch has won numerous awards, including the Maxwell Finland Award for Lifetime Scientific Achievement from the National Foundation for
Infectious Diseases (NFID), the Lifetime of Leadership Award from the International Antiviral Society-USA (IAS-USA),
and the Mentor Award from the Infectious Diseases Society of America (IDSA).
22
AIDS@30 Engaging to End the Epidemic | Session 5: The Future of HIV Treatment
Participants:
Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University,
and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious disease at Massachusetts General Hospital, and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to
Harvard Medical School in 2002, where he is Professor of Medicine and Director of AIDS Research, Brigham & Women’s Hospital. He currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group, and as an Associate Editor of the Journal of Infectious Diseases. In January 2012, he will become Chief of the Division of Infectious
Diseases at Brigham and Women’s Hospital. His research interests focus on antiretroviral therapy and drug resistance.
Dennis C. Liotta, PhD is the Samuel Candler Dobbs Professor of Chemistry at Emory University, where he has been a
professor for 35 years. He is currently the Director of the Emory Institute for Drug Discovery, as well as Co-Director of the
Republic of South Africa Drug Discovery Training Program and Editor-in-Chief of ACS Medicinal Chemistry Letters.
Dr. Liotta has authored over 200 research publications and holds approximately 70 U.S. patents. Over the last 25 years
he has also developed experience in the discovery and development of pharmaceuticals. He has been a consultant to several major pharmaceutical firms, including Merck, Glaxo, Burroughs Wellcome, and Johnson & Johnson.
He serves (or has served) on the Scientific Advisory Boards of several small biopharmaceutical companies, including
Altiris (scientific founder), Pharmasset (scientific founder), iThemba Pharmaceuticals (scientific founder, SAB Chair),
NeurOp, and FOB Synthesis. He is the inventor of several clinically important agents, including FTC (Emtriva®, Emtricitabine), 3TC (Epivir®, Lamivudine), Reverset® (DPC 817, D-D4FC), Racivir, Elvucitabine (L-D4FC) and MSX-122. He is a
Fellow of the Alfred P. Sloan Foundation, among numerous honors and awards.
Roger Pomerantz, MD is Global Head of the Infectious Diseases Franchise and Senior Vice President at Merck & Co,
Inc., in charge of all anti-viral, anti-bacterial, anti-fungal and anti-parasitic agents, including global strategy. Prior
to joining Merck in 2010, Dr. Pomerantz was President of Tibotec Pharmaceuticals Ltd., the Virology and Infectious
Diseases Research and Development Company within Johnson & Johnson. Under his leadership, the company
launched Prezista, the first true second generation anti-HIV protease inhibitor, and Intelence, the first second generation anti-HIV non-nucleoside reverse transcriptase inhibitor. From 1990–2005, he was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for
Human Virology and Biodefense at the Thomas Jefferson University and Medical School in Philadelphia. Dr. Pomerantz
received his post-graduate training in Internal Medicine and Infectious Diseases and Virology at the Massachusetts
General Hospital and post-doctoral research training in Molecular Retrovirology at Harvard Medical School and the
Whitehead Institute of the Massachusetts Institute of Technology, in the laboratory of Nobel Laureate David Baltimore
(1988–1990).
Paul Stoffels, MD is Worldwide Chairman of Janssen, Pharmaceutical Companies of Johnson & Johnson. Dr. Stoffels
is leading the growth of the pharmaceutical business through R&D, partnerships and acquisitions. In his previous role
as Global Head, Pharmaceutical R&D, he was instrumental in driving the growth of the pipeline of new medicines.
He created one R&D organization across the pharmaceutical companies of Johnson & Johnson with a focus on
discovering and developing new and innovative treatments for unmet medical needs. From 1997 until 2002, Dr.
Stoffels was Chairman of Tibotec and Chief Executive Officer of Virco, two biotech companies based in Belgium,
which he continued to lead after their acquisition by Johnson & Johnson. At Tibotec, he led the development of HIV
products, PREZISTA and INTELENCE. Dr. Stoffels began his career as a physician in Africa, focusing on HIV and tropical
diseases research. When he returned to Belgium, he assumed responsibility for the infectious disease drug development at Janssen in Beerse. Dr. Stoffels studied Medicine at the University of Diepenbeek and the University of Antwerp
in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium.
Session 5: The Future of HIV Treatment | AIDS@30 Engaging to End the Epidemic
23
Session 6: Is an HIV Vaccine Possible?
1:00 PM–2:30 PM
In recent years, there have been significant advances in the field of HIV vaccine
research, including the groundbreaking RV 144 trial in Thailand. What is the
future of HIV vaccine research, how will it be sustained, and who will lead the
global effort?
Key Questions:
s 7HAT DOES THE LATEST RESEARCH TELL ABOUT THE LIKELIHOOD OF DEVELOPING A VACCINE
s "ASED ON THE KNOWLEDGE AVAILABLE TODAY IS AN EFFECTIVE ()6 VACCINE SCIENTIlCALLY POSSIBLE
s 7HAT ARE THE MOST SIGNIlCANT SCIENTIlC OBSTACLES IN ()6 VACCINE RESEARCH
s (OW MUCH WILL IT COST TO lND OUT
s 4O WHAT EXTENT WILL VACCINE TRIALS BE AFFECTED BY THE INCREASED STUDY OF ANTIRETROVIRALS FOR PREVENTION
Perspective:
Anthony S. Fauci, MD is Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National
Institutes of Health. Since his appointment as NIAID director in 1984, Dr. Fauci has overseen an extensive research
portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases. Dr. Fauci also
is chief of the NIAID Laboratory of Immunoregulation, where he has made numerous important discoveries related
to HIV/AIDS and is one of the most-cited scientists in the field. Dr. Fauci, a member of the U.S. National Academy of
Sciences, has received numerous awards for his scientific accomplishments, including the National Medal of Science,
the Mary Woodard Lasker Award for Public Service, and the Presidential Medal of Freedom. He has been awarded 36
honorary doctoral degrees and is the author, coauthor, or editor of more than 1,100 scientific publications, including
several major textbooks.
Moderator:
Bruce Walker, MD is a Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator, and Director of the Ragon Institute of MGH, MIT and Harvard. In addition to his clinical duties as an infectious
disease specialist, his research focuses on cellular immune responses in chronic viral infections, with a particular focus
on HIV. He leads an international clinical and basic science research effort to understand how some rare people who
are infected with HIV, but have never been treated, can fight the virus with their immune system. Dr. Walker is also
an Adjunct Professor at the Nelson Mandela School of Medicine in Durban. There he collaborates with the Doris Duke
Medical Research Institute at the University of KwaZulu-Natal and is Principal Investigator in the HIV Pathogenesis
Program, an initiative to study the evolution of HIV and effective immune response to it and to train the next generation of African scientists. He is also on the Steering Committee for the KwaZulu-Natal Research Institute to build a
state-of-the art TB-HIV research facility at the heart of these dual epidemics in South Africa.
24
AIDS@30 Engaging to End the Epidemic | Session 6: Is an HIV Vaccine Possible?
Participants:
Robert C. Gallo, MD is Director of the Institute of Human Virology and Professor of Medicine at the University of
Maryland School of Medicine. Prior to co-founding the Institute in 1996, he spent 30 years at the National Cancer
Institute, where he headed the Laboratory of Tumor Cell Biology. He became world famous in 1984 for co-discovering
the human immunodeficiency virus (HIV) as the cause of AIDS and pioneering the development of the HIV blood
test, enabling HIV screening. His research also helped physicians develop HIV therapies to prolong the lives of those
infected with the virus, including a discovery in 1996 that a natural compound known as chemokines can block
the HIV virus and halt the progression of AIDS. His discoveries before the AIDS epidemic include the identification of
human retroviruses (HTLV-1, also the first known virus to cause leukemia, and HTLV-2), Interleukin-2, as well as a new
human herpes virus, HHV-6, later shown to cause roseola. Dr. Gallo’s research interests currently focus on the development of an effective HIV preventive vaccine and the development of innovative HIV therapies.
M. Juliana McElrath, MD, PhD is Senior Vice President and Member of Fred Hutchinson Cancer Research Center
(FHCRC); Professor, Department of Medicine, Lab Medicine & Global Health, University of Washington; and CoDirector of the Vaccine and Infectious Disease Division (VIDD). She is the Principal Investigator of the HVTN Laboratory
Program and Seattle Vaccine Trials Unit and has clinical attending responsibilities as an Infectious Diseases consult
for the Seattle Cancer Care Alliance and UW Hospital. Her current research pursues both a vaccine that will protect
against HIV-1 infection and a deeper understanding of the components of immunity that contribute to control of
HIV-1 disease. Dr. McElrath has built and maintains a successful international HIV vaccine laboratory program, and
conducts translational immunological research in humans in a multicenter setting. She has contributed a fundamental understanding of how HIV-1 enters the mucosa to establish infection, and mechanisms of potential reduced
susceptibility to infection in sero-negative persons repeatedly exposed to HIV-1. In conjunction with a highly productive research program, she has assumed a leadership role or been a major contributor in a number of integrated
programs at the national and international level to advance a coordinated effort to tackle the HIV epidemic through
prevention efforts.
Nelson L. Michael, MD, PhD is Director of the Division of Retrovirology at the Walter Reed Army Institute of Research
(WRAIR) and Director of the U.S. Military HIV Research Program (MHRP). He guided MHRP through completion of the
RV 144 HIV prime-boost vaccine study, a clinical trial that provided the world’s first demonstration that an HIV vaccine was possible. A Colonel in the United States Army Medical Corps, Dr. Michael entered his Army service in 1989 in
WRAIR’s Department of Vaccine Research and later served as the Chief of the Department of Molecular Diagnostics
and Pathogenesis. His research interests include HIV molecular pathogenesis and host genetics, HIV clinical research,
and HIV vaccine development. He is a Professor of Medicine, Uniformed Services University, and a Diplomat, American Board of Internal Medicine. Dr. Michael currently serves on numerous committees and working groups, including
President Obama’s Presidential Commission for the Study of Bioethical Issues, the Vaccine Research Center Scientific
Advisory Working Group, Office of AIDS Research Advisory Committee, AIDS Vaccine Research Subcommittee, Scientific Committee of the Global HIV AIDS Vaccine Enterprise, and the PEPFAR Scientific Advisory Board.
Jerald C. Sadoff, MD is Chief Medical Officer and Head of Development at Crucell in the Netherlands. Dr. Sadoff has
spent his entire career developing vaccines for a large number of bacterial, viral and parasitic diseases. At the Walter
Reed Army Institute of Research, he held joint appointments as Director, Division of Communicable Diseases and
Immunology and Associate Professor of Medicine at the Uniformed Services University of the Health Sciences. In 1995,
he became Executive Director of Clinical Development of Vaccines at Merck, developing and obtaining licensure
for eight vaccines. Dr. Sadoff joined the Aeras Global TB Vaccine Foundation where he became President and Chief
Executive Officer in 2003, developing the world’s leading portfolio on tuberculosis vaccine candidates. He is Chair of
the USAID Malaria Vaccine Scientific Consultants Group, chairs several Scientific Advisory Boards for NIH-sponsored
HIV vaccine efforts, serves on the NIAID AIDS Vaccine Research Working Group, the Scientific Advisory Board of the
NIH Vaccine Research Center, and the Scientific Advisory Board of the International AIDS Vaccine Initiative. Over the
last 35 years, he has authored over 300 articles, book chapters, and abstracts.
Session 6: Is an HIV Vaccine Possible? | AIDS@30 Engaging to End the Epidemic
25
Session 7: Funding the Global AIDS Response
3:00 PM–4:30 PM
Despite significant advancements, recent data suggest that only approximately
a third of those in need in low- and middle-income countries have access to
antiretroviral therapy. The most recent data indicate total global spending on
HIV/AIDS in 2009 was $15.9 billion, yet UNAIDS says billions more will be needed
to close the gap. How will the future global AIDS response be financed?
Key Questions:
s 4AKING INTO CONSIDERATION THE GLOBAL ECONOMIC SLOWDOWN WILL IT BE POSSIBLE TO SUSTAIN OR INCREASE
current AIDS funding?
s (OW SHOULD !)$3 FUNDING BE ORGANIZED AND ALLOCATED
s 7HAT SHOULD BE THE ROLE OF THE PRIVATE SECTOR
Perspective:
Michel D. Kazatchkine, MD is Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Dr. Kazatchkine has spent the past 25 years fighting AIDS as a leading physician, researcher, administrator, advocate,
policy maker and diplomat. Prior to joining the Global Fund in 2007, he was Professor of Immunology at Université
René Descartes and Head of the Immunology Unit of the Georges Pompidou Hospital in Paris. He has authored or
co-authored more than 500 articles in peer reviewed journals, focusing on auto-immunity, immuno-intervention and
pathogenesis of HIV/AIDS. Dr. Kazatchkine has played key roles in various organizations, serving as Director of the
National Agency for Research on AIDS in France from 1998 to 2005, Chair of the World Health Organization’s Strategic
and Technical Advisory Committee on HIV/AIDS from 2004 to 2007, member of the WHO’s Scientific and Technical
Advisory Group on tuberculosis from 2004 to 2007, and French Ambassador on HIV/AIDS and communicable diseases
from 2005 to 2007. He was the first Chair of the Global Fund’s Technical Review Panel from 2002 to 2005 and has
served as a Board member and Vice-Chair of the Board from 2005 to 2006.
Moderator:
Allan M. Brandt, PhD is Dean of the Graduate School of Arts and Sciences at Harvard University, where he is the
Amalie Moses Kass Professor of the History of Medicine. His work focuses on social and ethical aspects of health,
disease, medical practices, and global health in the twentieth century. He is the author of No Magic Bullet: A Social
History of Venereal Disease in the United States since 1880 (1987) and co-editor of Morality and Health (1997). He
has written on the social history of epidemic disease, the history of public health and health policy, and the history of
human experimentation, among other topics. His book The Cigarette Century: The Rise, Fall, and Deadly Persistence
of the Product that Defined America received the Bancroft Prize from Columbia University in 2008 and the Welch
Medal from the American Association for the History of Medicine in 2011. He has been elected to the Institute of
Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences. He is currently
writing about the impact of stigma on patients and health outcomes.
26
AIDS@30 Engaging to End the Epidemic | Session 7: Funding the Global AIDS Response
Participants:
Gregg Gonsalves has worked on behalf of people living with HIV since 1991. He is currently a fellow with the Open
Society Foundations where he is comparing the response to HIV, tuberculosis and maternal and child health in
Ukraine, South Africa and Brazil. He is also a fellow in the Department of Global Health and Social Medicine at
Harvard Medical School and in the Division of the Epidemiology of Microbial Diseases at the Yale School of Public
Health. In the 1990s, Gregg worked to streamline drug approval at the Food and Drug Administration and to improve
the conduct of AIDS research at the National Institutes of Health. Since 2000, he has focused on expanding access to
AIDS and TB drugs to all who need them around the world. He has co-founded three organizations: the Treatment
Action Group, the International Treatment Preparedness Coalition and the CD4 Initiative and worked for two others:
Gay Men’s Health Crisis and the AIDS and Rights Alliance for Southern Africa. He is a 2011 graduate of Yale College.
Robert Hecht, PhD joined the Results for Development as a Managing Director in April 2008, concurrent with the
establishment of the new Institute. He oversees a portfolio of projects analyzing policy barriers and proposing solutions
related to AIDS and vaccine financing, health financing reforms, and improving research and development and
access to new health technologies. Before coming to R4D, Dr. Hecht spent four years as Senior Vice President for
Policy and Advocacy at the International AIDS Vaccine Initiative and 20 years at the World Bank, where he occupied a number of senior posts, including head of the Bank’s central unit for Health, Nutrition, and Population; chief of
operations for the Human Development Network; and principal economist in the Latin America region. From 1987 to
1996, Dr. Hecht was responsible for World Bank sponsored studies and projects in health, nutrition, and education in
Africa and Latin America. Dr. Hecht was director of the Joint United Nations Program on HIV/AIDS (UNAIDS) from
1998 to 2001 and is the author of more than 40 articles, book chapters, and other publications.
Ira C. Magaziner founded the Clinton Health Access Initiative (CHAI) with former President Bill Clinton in 2002 and
currently serves as its Chief Executive Officer and Vice Chairman. He is also the Chairman of the Clinton Climate
Initiative (CCI). From 1993 through 1998, he served as Senior Advisor to President Clinton for Policy Development at
the White House. In this capacity, he supervised the development and implementation of the administration’s policy
for commercialization of the Internet and worked with First Lady Hillary Rodham Clinton on the development of the
President’s Health Reform Initiative. Mr. Magaziner also chaired a joint National Economic Council/National Security
Council Initiative to increase U.S. exports and was a member of the National Domestic Policy Council. Mr. Magaziner
is one of America’s most respected corporate strategists. Prior to his White House appointment, he built two successful
consulting firms and worked for the Boston Consulting Group in Boston, London, and Tokyo, helping major corporations develop their business strategies. He graduated from Brown University as valedictorian of the class of 1969, and
attended Balliol College, Oxford as a Rhodes Scholar.
Jean-Paul Moatti, PhD is an internationally recognized health economist, who has made a major impact on HIV/AIDS
access and equity issues. Dr. Moatti is Professor of Economics at the University of Aix-Marseille, South-Eastern France,
and Director of an INSERM (the French National Institute of Health) research group where since 2000 he has been
actively involved in research related to access to HIV treatment and equity in health systems of developing countries.
He has been the adviser for economic and social affairs to the Executive Director of the Global Fund Against AIDS,
Tuberculosis & Malaria (GFATM), and he has been recently appointed as Director of the Institute of Public Health that
coordinates all public research bodies in the field in France. He has extensively published in health economics as well
as biomedical and public health scientific journals.
John E. Tedstrom, PhD is President and CEO of GBCHealth. John joined GBCHealth in August, 2006, and since that
time has steadily expanded the organization’s reach, deepened relationships with key partners, and initiated important organizational reforms to make operations more cost-effective and programs more impactful. Since John took
over as Executive Director of GBCHealth in August 2006, membership has grown to include more than 200 companies
and organizations across the globe. John also led the organization’s growth from an exclusive focus on HIV/AIDS to
an agenda that included strong programs on tuberculosis and malaria beginning in 2007. Under John’s leadership,
the organization unveiled a broader public health mandate in June 2011. Prior to joining GBCHealth, John founded
and led the Transatlantic Partners Against AIDS (TPAA), an organization operating in Russia and Ukraine; served as
the director for Russia, Ukraine, and Eurasian Affairs for the U.S. National Security Council during President Bill Clinton’s
administration; worked as a economist and senior economist at the RAND Corporation; and held the Jacyk Chair at
the Columbia University School of International and Public Affairs in 2000–2001.
Session 7: Funding the Global AIDS Response | AIDS@30 Engaging to End the Epidemic
27
AIDS@30 Outcomes
The AIDS@30 conversation will continue beyond the symposium, as we advance
the initiative’s underlying goal of Engaging to End the Epidemic.
During and following the symposium, our audience, participants and the public
are invited to review excerpts from the sessions and add to the conversation online
at AIDSat30.org.
In addition to a symposium report, the symposium outcomes and key themes will
be summarized and examined further by key AIDS@30 leaders in a peer-reviewed
journal supplement, planned for publication ahead of the XIX International AIDS
Conference (AIDS 2012) in Washington, D.C., next July.
Please visit the symposium website for news and updates about these special
publications.
The Conversation Continues: AIDSat30.org
28
AIDS@30 Engaging to End the Epidemic | AIDS@30 Outcomes
Symposium Attendee List
Elaine Abrams
ICAP at Columbia University, Mailman
Deborah Birx
Centers for Disease Control
and Prevention
Chris Collins
amfAR, The Foundation for
AIDS Research
Nadia Abuelezam
Judie Blair
South Africa Development Fund
Georgette Adjorlolo-Johnson
AIDS Foundation
Ronald Bosch
Ellen Cooper
Boston Medical Center Division of
Pediatric Infectious Diseases
Myriam Afeiche
Evgenia Aga
Anu Agrawal
Olalekan Akanbi
Fadhlun Al-Beity
Boston University
Andreas Alfredsson
Now and Then Digital
Documentation AB
Kathleen Hennessy Amirault
Leah Anderson
Merck
David Bangsberg
Alexandre Barbosa
Universidade Estadual Paulista
Nomampondo Barnabas
Chris Hani Baragwanath Hospital
Donna Barry
Partners in Health
Ingrid Bassett
Candice Beaubien
Joan Beckwith
Philadelphia College of
Osteopathic Medicine
Noor Beckwith
and Harvard
Judy Bradford
Fenway Health
Linda Brady
Hoosen Coovadia
MatCH (Maternal, Adolescent and
Child Health)
Alice M. Cort
Deborah Cotton
Allan Brandt
Harvard University
Clyde Crumpacker
Harvard Medical School/Beth Israel
Deaconess Medical Center
Dan Brock
Michele Broemmelsiek
Catholic Relief Services
Jan-Walter De Neve
Kristin Brown
Brandt Burgess
NIH/NIAID
Victor DeGruttola
Shelly Dhir
ViiV Healthcare
Alberto Caban-Martinez
Sean Cahill
Fenway Health
Dazon Dixon Diallo
SisterLove, Inc.
John Dillon
ViiV Healthcare
Stephen Calderwood
Patricia Case
Fenway Health
Robert Dintruff
Abbott
Raphael Dolin
Monique Chaplin
Richelle Charles
Huabiao Chen
and Harvard
Miriam Chernoff
Harvard School of Public Health/Center
for Biostatistics in AIDS Research
Andrea Ciaranello
Joseph Colagreco
Peter Donaldson
Population Council
Bruce Donoff
Harvard School of Dental Medicine
Christopher Dunne
Felton Earls
Marilyn Edmunds
April Edrington
Wafaa El-Sadr
ICAP at Columbia University, Mailman
Symposium Attendee List | AIDS@30 Engaging to End the Epidemic
29
Karen Emmons
Harvard School of Public Health/
Dana-Farber Cancer Institute
M. Essex
Martha Henry
Hillary Goldhammer
Fenway Health
Staffan Hildebrand
Documentation AB
Natalie Exner
Gregg Gonsalves
PIDSC/Global Health and
Social Medicine
Mansour Farahani
William A. Graham
Harvard University
Martin Hirsch
Paul Farmer
Robert Grant
Gladstone Institute of Virology
and Immunology
Douglas Hopper
Anthony Fauci
National Institute of Allergy and
Infectious Diseases
Wafaie Fawzi
Mark Feinberg
Merck & Co., Inc.
Harvey Fineberg
Institute of Medicine
Jeffrey Flier
Kenneth Freedberg
Julio Frenk
Robert Gallo
Institute of Human Virology
Kathryn Galvin
Rajesh Gandhi
Alan Garber
Harvard University
Wilfredo García Beltrán
Sarah Gheuens
Isabelle Girault
Merck & Co., Inc.
Michelle Giuliana
Elizabeth Glaser
Heller School for Social Policy,
Brandeis University
30
Stephen Gluckman
University of Pennsylvania
Robert Greenwald
Legal Services Center of Harvard
Law School
Laura Guay
AIDS Foundation
Cara Guenther
Harvard College
Chirfi Guindo
Merck Sharp & Dhome Corp
Jessica Haberer
Jill Hagey
Yale University
Anders Hagstrom
Documentation AB
Donald Hamel
Evelynn Hammonds
Harvard University
Leslie Hardy
The Merck Company Foundation
Padmini Harigopal
Fenway Health
Robert Hecht
Results for Development
Shirin Heidari
Nicholas Hellmann
AIDS Foundation
AIDS@30 Engaging to End the Epidemic |Symposium Attendee List
Sharon Hillier
University of Pittsburgh
Hortencia Hornbeak
NIH/NIAID/DEA/SRP
Mary Jo Hoyt
University of Medicine and Dentistry of
New Jersey
David Hunter
Emily Hyle
Mark Ingaciola
Harvard University
Ulf Janzon
Merck Sharp & Dohme Corp
Seth Kalichman
University of Connecticut
Phyllis Kanki
Elly Katabira
Vaibhav Katkade
EMD Serono
Michel Kazatchkine
The Global Fund to Fight AIDS,
Tuberculosis and Malaria
Keitumetse Kebaanetswe
Champions for an HIV Free Generation
Michelle Kendall
Orla Kennedy
Tamera Kingston
David Knight
Anti Slavery International
David Knipe
Constance Khabe Koloi
Arba Kokalari
Now and Then Digital Documentation
AB/Face of AIDS
Daniel Kuritzkes
Brigham and Women’s Hospital/
Ana Langer
Charles Lyons
AIDS Foundation
Iain MacLeod
Ira Magaziner
Clinton Health Access Initiative
Wendy Mariner
Boston University
Richard Marlink
Peter Muiruri
Joia Mukherjee
Oliver Murima
Jeffrey Murray
FDA/Division of Antiviral Products
Angela Mushavi
Elizabeth Glaser Pediatric AIDS Foundation/Ministry of Health and Child Welfare
Ramadhani Mwiru
Kristine Laping
Zene Matsuda
Institute of Medical Science, University
of Tokyo
Samantha Lattof
Kenneth Mayer
Fenway Health
Sylvia Lee
Bethany Maylone
Florence Ngobeni-Allen
AIDS Foundation
Ann Lee
Helen McDowell
ViiV Healthcare
Julia Njoroge
Sandra Lehrman
Merck & Co., Inc.
Julie McElrath
Fred Hutchinson Cancer
Research Center
Anders Nordström
Ministry for Foreign Affairs
Alyssa Letourneau
Massachusetts General Hospital/
Brigham and Women’s Hospital
Edward Nardell
Joel Novendstern
Ranbaxy
Kathy Melbourne
Gilead Sciences
Tej Nuthulaganti
Susan Levin
Nelson Michael
Walter Reed Army Institute of Research
Elinor Levy
Matthew Mimiaga
Fenway Health
Humberto Licona
Festus Gontebanye Mogae
Champions for an HIV-Free Generation
Judy Lieberman
Immune Disease Institute
Rosemary Moleski
Boston Medical Center
Jean Pape
Weill Cornell Medical College and
Centres GHESKIO
Dominique Limet
ViiV Healthcare
Antigoni Morou
and Harvard
Elizabeth Penniman
AIDS Foundation
Christopher Mtamakaya
Ben Perkins
Fenway Health
Expeditho Mtisi
Vivian Peterson
Lynn Community Health Center
Jean Paul Moatti
AVIESAN/INSERM
Benjamin Phelps
USAID
Vamsi Mootha
Roger Pomerantz
Merck & Co., Inc.
Jane Lindsey
Dennis Liotta
Emory Institute for Drug Discovery
Shahin Lockman
Brigham and Women’s Hospital/
Elena Losina
Conall O’Cleirigh
Fenway Health
Nancy Padian
University of California, Berkeley
Symposium Attendee List | AIDS@30 Engaging to End the Epidemic
31
John Pottage
ViiV Healthcare
Roger Shapiro
Martha Vibbert
SPARK, Boston Medical Center
Kathleen Powis
David Shapiro
Jon Vincent
Fenway Health
Julie Rafferty
Holly Shepherd
South Africa Development Fund
Vish Viswanath
Harvard University
Christen Reardon
Renslow Sherer
University of Chicago
Rochelle Walensky
Michael Reich
Mariângela Simão
UNAIDS
Todd Reinhart
University of Pittsburgh
Jonathon Simon
Boston University, Center for Global
Health & Development
Bruce Walker
and Harvard
Sari Reisner
Fenway Health
Joseph Rhatigan
Jessica Riviere
Bristol-Myers Squibb
Christopher Rowley
Elizabeth Russell
Naomi Rutenberg
Population Council
Edward Ryan
Massachusetts General Hospital/
Harvard University
Jorge Saavedra
AIDS Healthcare Foundation
Jerald Sadoff
Crucell
N.M. Samuel
Concern for AIDS Research
and Education
Maheswar Satpathy
National Centre in HIV Social Research,
University of New South Wales (UNSW)
Paul Schaper
Merck
32
R.J. Simonds
AIDS Foundation
Alan Whiteside
Health Economics and HIV/AIDS
Research Division (HEARD)
Phill Wilson
The Black AIDS Institute
Laura Smeaton
Dyann Wirth
Harvard University
Suniti Solomon
YRG CARE
Robin Wood
Desmond Tutu HIV Centre
Donna Spiegelman
Thomas Zeltner
Global Patient Safety Forum
Ellie Starr
Jose Zuniga
International Association of Physicians in
AIDS Care
Paul Stoffels
Johnson & Johnson
Jeffrey Sturchio
Global Health Council
John Tedstrom
GBCHealth
Donald Thea
Boston University
Meredy Throop
Partners in Health
Idia Thurston
Children’s Hospital Boston
Katie Tiger
George R. Seage III
Ildiko Toth
and Harvard
Celicia Serenata
Clinton Health Access Initiative (CHAI)
Virginia Triant
Tracy Shahan
NIH/NIAID
Rodney Vanderwarker
Fenway Health
AIDS@30 Engaging to End the Epidemic |Symposium Attendee List
List reflects registration at time of press.
Photos: CDC Connects; CDC/ Cheryl Tryon, Stacy Howard; CDC/ Hsi Liu, Ph.D., MBA, James Gathany; CDC/ Dawn Arlotta; Flávio Takemoto
The Joseph B. Martin Conference Center | Harvard Medical School | 77 Avenue Louis Pasteur | Boston, Massachusetts

the AIDS@30 Symposium Program

Transcription

Similar documents

Babies born from HIV/AIDS positive mothers

B U CA I

Full Text

: Al ahram hebdo (journal egyptien) 2007

- Malaysian AIDS Council

Press Release - African Union

Reach Out brochure - Reach Out Nkokonjeru Parish Reach Out

Archived Field Experiences Aarti Agarwal, HIV

15th Amendment - Princeton University

English - Women In Europe